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Introduction: one of the most common reported chief complaints in 
visits to pediatricians is constipation. Although in a majority of cases 
with no anatomical defect, dietary manipulation, stool softeners, and 
oral laxatives are successful, some patients fail to respond.
Internal Anal Sphincter (IAS) Achalasia is one of the causes of constipation.
It results in failure of IAS relaxation and has similar clinical presentation 
to Hirschsprung’s disease with absence of rectosphincteric inhibitory 
reflex on anorectal manometry (ARM) and presence of ganglion cells 
on rectal biopsy.
Although posterior internal anal sphincter myectomy (ISM) is considered 
the standard treatment for IASA, some cases fail to respond and present 
with intractable constipation which may be associated with soiling.
This research aims to assess the role of botox injection for treatment of 
patients who presented with intractable constipation and have already 
beentreated by posterior IAS myectomy.
Materials and Methods:Internal anal sphincter Botox injection 
was performed (with a dose of 20 U/Kg) in 14 patients with internal 
anal sphincter achalasia (IASA); who had presented with intractable 
constipationafter being treated by posterior internal anal sphincter 
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Introduction
One of the most common reported childhood chief 
complaints is constipation, comprising up to 1 in 5 
of pediatric gastroenterological complaints and 3% 
of all visits to pediatricians.1-4
Although in the majority of cases with no 
anatomical defect, dietary manipulation, stool 
softeners, and oral laxatives are successful, some 
patients fail to respond to conventional treatment.5
For the first time, Hurst in 1934 proposed that one 
of the possible pathogenetic mechanisms of these 
types of idiopathic constipation might be internal 
anal sphincter(IAS) relaxation failure rather than 
a spasm.6
Internal Anal Sphincter (IAS) Achalasia,is 
identified in up to 4.5% of childhood chronic 
constipations; with similar clinical presentation 
to Hirschsprung’s disease and is diagnosed by 
the absence of rectoanal inhibitory reflex (RAIR) 
in anorectal manometry (ARM), the presence of 
ganglion cells and normal Ach Eactivity on rectal 
suction biopsy and no transitional region on barium 
enema. 7-10
Although posterior myectomy with all its reported 
complications has been considered as the treatment 
of choice for IASA for over 50 years; since 
1997, after Langer and Birnbaum’s preliminary 
experience with intrasphincteric botulinum toxin 
injection in Hirschsprung’s disease patients with 
myectomy. Patients were followed for 2 years after injection.
Result: of all 14 patients with persistent constipation (resistant to oral 
laxatives), 12 patients (85.7%) had regular bowel function for more than 
6 months after botox injection therapy (P < 0.05).
Of all 14 patients that had needed rectal enema for defecation, no 
patient needed rectal enema after botox injection therapy (P < 0.05). 
Of 5 patients with fecal soiling before botox injection therapy (4 had 
occasionalsoiling, and 1 had soiling every day without social problems) 
only a single patient experienced transient fecal soiling for 2 weeks after 
botox injection therapy (P < 0.05).
No patient needed another botox injection in 2 years of follow up.
Conclusion: IAS Botox injection therapy (BIT) was successfully used to 
manage IASA patients who had presented with intractable constipation 
after posterior myectomy. This method significantly reduces the need 
for laxatives and rectal enema; and improves constipation, fecal soiling 
and bowel movements at the same time.
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persistent constipation after pull-through surgery, 
satisfying short-term results have been reported 
following this less invasive procedure.9, 11-13
However, some IAS Achalasia patients failed to 
respond even to posterior myectomy and presented 
with intractable constipation.
In this study, we evaluate botox injection treatment 
(BIT) in IAS achalasia patients presented with 
intractable constipation after posterior myectomy.
Materials and Methods
The records of 35 patients suffering from internal 
anal sphincter achalasia (IASA) whom had 
been treated by posterior internal anal sphincter 
myectomy during 2011-2015 were reviewed.
Posterior myectomy was carried out at the dentate 
line toward the proximal and samples were 
taken.  All of our cases suffered from intractable 
constipation along with soiling or not. Before 
undergoing surgery, all patients had a barium 
enema and anorectal manometry. All patients had 
an absence of rectoanal inhibitory reflex (RAIR) on 
anorectal manometry(ARM), normal rectal biopsy 
and no transitional region on barium enema.
In all there were 14 patients (8 boys and 6 girls) 
with a Mean age of 95 months.Their symptoms 
persisted and they all had Constipation Grade3, 
Resistant to laxatives and diets and 5 had fecal 
soiling. 
Botox was mixed with 5ml of non-preserved 
sterile saline and 20U/kg was injected by a 
27-gauge needle under general anesthesia, in the 
lithotomy position, at the level of dentate line, in 
four quadrants into the intersphincteric groove. 
Laxatives were continued after injection in all 
cases.
All patients were clinically followed up for up to 
2 years, symptoms, defecation’s pattern and stool 
diameter were evaluated.
Improved defecation pattern for more than 4 weeks 
was considered successful.
All collected data were statistically analyzed by 
SPSS application.
A P-value of less than 0.05 was considered 
significant.
Results
Of all 14 patients with persistent constipation 
(resistant to oral laxatives and oral softeners), 12 
patients (85.7%) had regular bowel function for 
more than 6 months after botox injection therapy 
(P < 0.05).
Of all 14 patients that had needed rectal enema for 
defecation, no patient needed rectal enema after 
botox injection therapy (P < 0.05).
Of 5 patients who had fecal soiling before botox 
injection therapy (4 had occasional soiling and 
1 experienced soiling every day), only a single 
patient experienced transient fecal soiling for 2 
weeks after botox injection therapy (P< 0.05).
Although all 14 patients were resistant to oral 
laxatives, no patient reported any defecation 
problem with laxatives after botox injection 
therapy. (P < 0.05)
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No patient needed another botox injection in 2 
years of follow up.
Discussion
The internal anal sphincter(IAS) is constructed by 
a special smooth muscle ring that has a major role 
in maintaining the anorectal continence and resting 
pressure. Any physical or functional IAS disorder, 
(IAS resting pressure or incomplete RAIR) results 
in passive incontinence or constipation and 
subsequentobstructive symptoms, due to failure of 
IAS relaxation.11, 14
Although the specific pathogenesis and 
pathophysiology of IAS Achalasia is yet to be 
known, but altered intramuscular innervations, 
nitrergic nerve depletion, cholinergic hyperplasia 
and abnormal peptidergic innervation are suggested 
to be responsible.15-17
In a study by Puri and Oueit was shown that in 
IASA PGP 9.5-immunoreactive and synapsin 
I-positive nerve fibers is reduced or absent.17
Achalasia is one of the uncommon causes of 
childhood constipation due to the IAS relaxation 
failure. Rectoanal inhibitory reflex(RAIR) is the 
relaxation of IAS due to distention of the rectum 
and any abnormality regarding this reflex or 
orhypertonicity of IAS can result in constipation.13
A theory was suggested by Hurst in 1934 proposing 
that IAS relaxation failure as one of the possible 
pathogenic mechanisms of idiopathic constipation 
and not its spasm.6
IAS achalasia clinically presents similar to 
Hirschsprung’s disease, having symptoms 
and signs such as delayed meconium passage, 
abdominal distention, vomiting and constipation 
with or without soiling.These presentations were 
formerly attributed to Hirschsprung’s disease and 
the disease was sometimes classified as ultra-short 
segment type of Hirschsprung.6, 16
Doodnah and Puri published diagnostic criteriafor 
IASA:
An ARM which shows absence of rectosphincteric 
reflex and presence of marked rhythmic activity of 
IAS muscle on rectal balloon inflation, presence of 
ganglion cells with normal AchE activity in rectal 
suction biopsy and the absence of transitional 
region on enema.10, 14
Also Hirakawa et al. reported diagnostic 
histochemical criteria for IAS achalasia: increased 
AchE-positive nerves and absence of NADPH-
diaphorase activity in the IAS biopsy.19
But patients with IAS Achalasia may have some 
medical presentations that differentiate them from 
the control patients:
They have less fecal soiling, less withholding 
behavior and earlier onset of symptoms starting at 
birth in 40% of cases.
In IAS achalasia, the Basal range of internal anal 
sphincteric resting pressure is about 45-150 mmHg, 
while the normal range is 33-100 mmHg.
A pressure of 40 to 300 ml (mean 146 ± 82 ml, 
normal value < 20 ml) is the threshold for rectal 
sensation.16
Posterior IAS myectomy with all its reported 
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complications has been considered as the treatment 
of choice for IASA for over 50 years, yet,  since 
1997, after Langer and Birnbaum ‘s preliminary 
experience with intrasphictpncteric botulinum 
toxin injection in HD patients with persistent 
constipation after pull-through surgery, satisfying 
short-term results have been reported following 
this less invasive procedure.9, 11-13
Botulinum toxin is a powerful neurotoxin that 
blocks acetylcholine release at neuromuscular 
junctions. 5, 20
This toxin has been successfully used to treat 
hypertonicity of both striated and smooth muscles 
for therapeutic and aesthetic purposes.  
Nowadays (over a century and a half since German 
physician John Muller came up with the term 
“botulism” in 1869, and almost 4 decades since 
the ophthalmologist Alan B. Scot used botulinum 
neurotoxin-A (BoNT-A) to treat strabismus in 
humans in 1979), botulinum toxin(botox) has been 
increasingly used for aesthetic purposes (wrinkle 
treatment for glabellar and perioral lines) and also 
therapeutic purposes (treatment for strabismus, 
esophageal achalasia, chronic constipation, chronic 
anal fissure, torticollis, blepharospasm, biliary 
dyskinesia and etc).21
Botulinum toxin acts on the neuromuscular 
junction by interfering with acetylcholine release 
from presynaptic cholinergic neurons; so BIT 
theoretically could have similar effects to posterior 
myectomy, without the potential long-term 
complications resulting from with permanent 
damage to the sphincter.16, 20
Nevertheless, BIT failure was reported in some 
patients, but it’s not clear whether it was a failure of 
treatment itself or was the result of other problems 
such as insufficient dose, injecting outside of 
internal anal sphincter or misdiagnosis.
In a similar study by Ciamarra P. et al on 20 patients, 
eight patients experienced bowel movement within 
2 days and 18 cases within 3 days of the BIT. Two 
cases remained constipated for more than 3 days 
and were considered treatment failures.Although in 
some of these failure cases repeating the treatment 
were helpful;thus repeating the treatment should be 
carried out before considering a child a treatment 
failure. Sixty percent of parents rated the treatment 
excellent; it was considered excellent in 35% of 
physician.16
But according to our study, none of the patients 
needed a repeat of IAS injection.
In the study byIrani K. Rodriguez L., 24 patients 
with constipation who hadan elevated IAS resting 
pressure underwent botox injection in the IAS 
and were followed for 6 months.In 22 of the 24 
patients constipation improved,with the duration 
of treatment efficacy varying from 1 week to 1 
year. In 12 patients lasting at least 6 months.13
In a study by Foroutan. H. et al in 2008, 28 patients 
with IAS were treated in two groups with either 
posterior internal anal sphincter myectomy or 
intrasphicteric botox injection to compare their 
efficacy for the treatment of internal anal sphincter 
achalasia (IASA). In either groups, the same 
efficacy was reported, also intrasphincteric botox 
injection was recommended as a less invasive 
treatment which should be considered as first line 
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therapy in IASA; not only because of its similar 
local effect as posterior internal anal sphincteric 
myectomy, but also its ability to improve visceral 
dysautonomia and bowel motility at the same time.7
In another study by Almoutaz A. Eltayeb et al on 
the role of botulinum toxin in the management of 
chronic constipation in 20 patients, 6 cases had an 
excellent response,12 cases experienced a good 
response but in 2 cases the response was poor and 
thus needed another injection. The duration of 
response was 3 to 6 months.5
The study of Dan Carter and Ram Dickman in 
2018 showed that BTX-A treatment is effective for 
the treatment of obstructive symptoms after pull-
through surgery for Hirschprung Disease as well as 
for the treatment of IAS Achalasia.22
In a study by Jin-Yang Liu, a 16-year-old patient 
with congenital megacolon and difficulty of bowel 
movement for more than 10 years, was successfully 
treated with Botox injection.23
In a meta-analysis by Friedmacher and Purion 
the efficacy of posterior IAS myectomy versus 
intrasphincteric Botox injection in IAS achalasia, 
in the botox group, rate of non-response and need 
for subsequent surgery and also transient fecal 
incontinence was significantly higher ( P=.04, P< 
0.0001 respectively).
Also, a good response to treatment demonstrated by 
regular bowel movements were considerably more 
in the posterior IAS myectomy group(P=0.04). 11
As mentioned before, posterior IAS myectomy 
has been the treatment of choice for IAS achalasia 
for over half of a century and appears to be 
more effective, but IAS botox injection is also a 
less invasive alternative treatment and due to its 
transient effect, all complications are assumed to 
be temporary.
In our study, IAS achalasia patients who had been 
managed with posterior myectomy and presented 
with intractable constipation were successfully 
treated with IAS botox injection, as it significantly 
reduced the need for laxatives and rectal enema, 
improved constipation, fecal soiling and bowel 
movements with a significant P-value of 0.05.
Conclusion
In conclusion, IAS Botox injection therapy (BIT), 
is a less invasive and symptom-relieving treatment 
to manage IASA patients presented with hyper-
spasticity-induced intractable constipation after 
posterior myectomy, But it needs more long-term 
follow-up.
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